product Name:Dactinomycin
- 3H-Phenoxazine-1,9-dicarboxamide, 2-amino-N,N'-bis[hexadecahydro-2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxo-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-4,6-dimethyl-3-oxo-; hbf 386; Lyovac cosmegen; Meractinomycin; Oncostatin K; X 97; Actactinomycin A IV; Actinomycin 7; Actinomycin AIV; Actinomycindioic D acid, dilactone; Actinomycin C1; actinomycin cl; Actinomycin D; (-)-actinomycin d; actinomycin i; Actinomycin I1; Actinomycin IV; Actinomycin-[threo-val-pro-sar-meval]; Actinomycin X 1; actinomycin x i; actinomyein-theo-val-pro-sar-meval; ACTO-D; AD; Dilactone actinomycindioic D acid; Dilactone actinomycin D acid; C1; Cosmegen; Dactinomycin D; dactinomyein d; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[2,5,9-trimethyl-6,13-bis(1-methylethyl)-1,4,7,11,14-pentaoxooctadecahydrocyclopenta[i][1,4,7,13]oxatriazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; 2-amino-4,6-dimethyl-3-oxo-N,N'-bis[(6S,9R,10S,13R,18aS)-2,5,9-trimethyl-1,4,7,11,14-pentaoxo-6,13-di(propan-2-yl)hexadecahydro-1H-pyrrolo[2,1-i][1,4,7,10,13]oxatetraazacyclohexadecin-10-yl]-3H-phenoxazine-1,9-dicarboxamide; ACTD
- 50-76-0
- 200-063-6
- C62H86N12O16
- 1255.417
- InChI=1/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22,27-30,33-34,36-37,42-45,48-49H,17-20,23-26,63H2,1-16H3,(H,65,80)(H,66,81)(H,67,78)(H,68,79)/t33-,34-,36+,37+,42-,43-,44+,45+,48+,49+/m1/s1
- 1.426g/cm3
- 241-243℃
- 1386.048°C at 760 mmHg
- 1.656
- 792.053°C
- SOLUBLE
- 0mmHg at 25°C
-
T+:Very toxic;
-
R28:;
R40:;
R61:;
-
S1:;
S45:;